Companies /Healthcare
Biogen Inc
NASDAQ: BIIB Drug Manufacturers - General
$252.26
▲ $1.57 (+0.63%) today
Markets closed · 5:14am ET

Biogen (BIIB) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
83%
EPS beat rate
+30.18%
Avg. EPS surprise
Consecutive EPS beats
BIIB vs Market · 30-day return after each reportBIIBS&P 500
0%+8%+16%+9.0%+6.7%Q1 25+9.1%+1.3%Q2 25+20.4%+0.3%Q3 25−5.3%−2.1%Q4 25−1.1%+6.6%Q1 26+4.4%+5.5%Q2 26
0%+8%+16%Q1 25Q3 25Q1 26
BIIB EPS Trend · estimate vs actualEstimateActual
$0$2$4$6$3.04$3.02Q1 25$3.87$5.47Q2 25$3.88$4.81Q3 25$1.63$1.99Q4 25$2.95$3.57Q1 26$2.07$3.60Q2 26
$0$2$4$6Q1 25Q3 25Q1 26
BIIB Revenue Trend · estimate vs actualEstimateActual
$0$800.0M$1.6B$2.4B$2.2B$2.4BQ1 25$2.3B$2.6BQ2 25$2.3B$2.5BQ3 25$2.2B$2.3BQ4 25$2.2B$2.5BQ1 26$2.5B$2.7BQ2 26
$0$800.0M$1.6B$2.4BQ1 25Q3 25Q1 26

How Often Does Biogen Beat Earnings Estimates?

Biogen beat EPS estimates in 5 of its last 6 reported quarters, and has beaten 5 quarters in a row.

BIIB quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 $3.60 est. $2.07 +73.61% $2.7B est. $2.5B +11.37%
Q1 2026 $3.57 est. $2.95 +20.93% $2.5B est. $2.2B +10.22%
Q4 2025 $1.99 est. $1.63 +22.09% $2.3B est. $2.2B +3.42%
Q3 2025 $4.81 est. $3.88 +23.88% $2.5B est. $2.3B +8.20%
Q2 2025 $5.47 est. $3.87 +41.31% $2.6B est. $2.3B +13.90%
Q1 2025 $3.02 est. $3.04 −0.72% $2.4B est. $2.2B +8.80%

Figures from SEC filings and company reports. Not investment advice.